May 9 |
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
|
May 9 |
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
|
May 9 |
Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
May 9 |
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript
|
May 8 |
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
|
May 8 |
Supernus Pharmaceuticals reports mixed Q1 results; reaffirms FY24 outlook
|
May 8 |
Supernus Announces First Quarter 2024 Financial Results
|
May 7 |
Supernus Pharmaceuticals Q1 2024 Earnings Preview
|
May 7 |
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for QelbreeĀ® (Viloxazine XR) in Latin America
|
May 7 |
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
|